The clinical-stage biopharma Vaccitech (Nasdaq:VACC) has appointed Nadège Pelletier as its new chief scientific officer. She will lead scientific teams in drug discovery and platform development at the company and will oversee its technical strategy. Vaccitech is a UK-based biotech that develops vaccines and immunotherapies. “It’s an exciting time to be joining Vaccitech,” Pelletier said in…